Lincoln D. Nadauld, M.D., Ph.D.
President, CEO, Culmination Bio, Inc.
Dr. Lincoln Nadauld founded the Intermountain Precision Genomics program and successfully led the clinical implementation of precision health across Intermountain Healthcare’s 24 hospitals and 160 physician clinics while serving as Intermountain Healthcare’s Chief of Precision Health and Academics. Nadauld conceived of and led the Heredigene, Population Study — a collaborative effort to collect and perform whole genome sequencing on 500,000 participants in the Intermountain system. Nadauld’s work was recognized with the Utah Governor’s 32nd Annual Science Medal for Industry, which is the highest civilian award to be bestowed by the state of Utah and honors significant contributions to science and technology. Dr. Nadauld also received the 2020 C2 Catalyst for Precision Medicine award, honoring those who improve personalized treatment for cancer patients. He was also named a "Top 50 Healthcare Innovator" by Modern Healthcare. Dr. Nadauld has published extensively, with more than 50 peer-reviewed scientific papers in leading scientific journals. He has also served as an editor for the Journal of Clinical Oncology-Precision Oncology.
Dr. Nadauld recently co-founded and was appointed President and CEO of Culmination Bio, a biotechnology data and discovery company spun out of Intermountain Healthcare. Culmination utilizes electronic health data combined with biological data from millions of patient cases to discover better health, including novel diagnostic tests, therapeutic targets, and care process models.
Senior Vice President of External Affairs, Tempus
Lauren Silvis serves as Senior Vice President of External Affairs, overseeing regulatory, public policy and government affairs. Silvis most recently served as the Chief of Staff of the U.S. Food and Drug Administration. Prior to that role, she was the Deputy Center Director for Policy in FDA’s Center for Devices and Radiological Health. At the FDA, she advanced policies on clinical testing, precision medicine, and digital health. Silvis was also a partner at Sidley Austin LLP, focusing on FDA regulation of pharmaceuticals and medical devices. She graduated from Duke University and earned her law degree from Georgetown University Law Center.
Mark P. Stevenson, M.B.A.
Camillus Life Sciences
Mark has over 30 years of experience in the life sciences industry, with strategic and operational leadership skills setting strategic direction and growth aspirations of complex, innovation-focused life science businesses.
He is the former Chief Operating Officer of Thermo Fisher Scientific in Boston, MA, and previously served as the President and Chief Operating Officer of Life Technologies in Carlsbad, CA, and President of Applied Biosystems in Foster City, CA.
His experience spans globally and includes time in Europe, Asia, and the United States, where he has spent the bulk of his life sciences career based between San Francisco, San Diego, and Boston. Throughout this time, he has worked with innovative fledgling start-ups and large multinational life science companies.
Mark has extensive board experience working with multiple public company boards and has served on nonprofit boards establishing strategy and facilitating goals as well as an advisor for government life sciences industries. He currently serves on the board of Ingersoll Rand and the Personalized Medicine Coalition.
Michael Sherman, M.D., M.B.A., M.S.
Chief Medical Officer, Point32Health
Dr. Michael Sherman is chief medical officer of Point32Health, providing clinical medical leadership to enhance quality of care and outcomes for health care consumers. He is responsible for medical trend management and assessing clinical partnerships, clinical innovations, and models of care. He also oversees medical policies and guidelines, including disease and care management services and wellness offerings that enhance the whole-person health care approach.
Michael was previously chief medical officer and senior vice president for health services at Harvard Pilgrim Health Care, which he joined in 2011. A pioneer in developing innovative, outcomes-based reimbursement models that engage providers and pharmaceutical and diagnostics companies, he is credited with cementing Harvard Pilgrim’s position as a leader among insurers in crafting agreements that tie drug payments to performance.
Michael is responsible for overseeing the Harvard Pilgrim Health Care Institute, which encompasses the Department of Population Medicine at Harvard Medical School—the nation’s only appointing medical school department based in a health plan. He is also a faculty member of the department and previously practiced as a cardiac anesthesiologist. He holds board appointments with several nonprofits, including the Institute for Clinical and Economic Review, the Personalized Medicine Coalition, the Harvard Business School Healthcare Initiative, the Center on Media and Child Health, the Museum of Science, and the Network for Excellence in Health Innovation.
Antonio L. Andreu, M.D., Ph.D.
Scientific Director, EATRIS (European Infrastructure for Translational Research)
Toni is an M.D., Ph.D. specialized in genetics and genomics of rare diseases. He has been working in the field of neuromuscular disorders from the translational perspective of the pipeline, from basic science to the development of cell and animal models and clinical research.
After working at Columbia University in New York on mitochondrial disorders from 1998 to 2001, he moved to Barcelona to create the Neuromuscular Lab at the Vall d’Hebron Research Institute where he became Director of the Neurosciences Research Program.
He has also been extremely active in the field of policy-making, and has held positions as the Director of the Spanish National Institute of Health Carlos III as well as the Director General for Research and Innovation at the Catalan Ministry of Health.
Vice President, Policy and Research, PhRMA (Pharmaceutical Research and Manufacturers of America)
Randy Burkholder is Vice President of Policy and Research at the Pharmaceutical Research and Manufacturers of America. Mr. Burkholder leads PhRMA's work on policy solutions for supporting continued biopharmaceutical innovation and high-quality, patient-centered health care, including payment and delivery reform, quality measurement, appropriate use and patient adherence, evidence-based medicine and health technology assessment, value of innovation and personalized medicine. Mr. Burkholder represents PhRMA at federal agencies and advisory bodies including the Medicare Evidence Development and Coverage Advisory Committee, the Centers for Medicare and Medicaid Services' Technical Expert Panel on oncology, and the Federal Coordinating Council for Comparative Effectiveness Research. He also serves on the Steering Committee of the Partnership to Improve Patient Care and the advisory committee for the Turning the Tide Against Cancer initiative.
Mr. Burkholder has over 20 years of experience in health care policy, advocacy, and communications in the medical technology and pharmaceutical industries. Prior to joining PhRMA, Mr. Burkholder was Associate Vice President for Public Affairs at AdvaMed, the leading association of the medical device and diagnostics industries.
Chairman and CEO, Exact Sciences
Kevin Conroy is the Chairman and Chief Executive Officer of Exact Sciences. Mr. Conroy led Exact Sciences through the development, clinical study, regulatory approval, and commercialization of its non-invasive colorectal cancer screening test, Cologuard®. In 2019, Exact Sciences’ acquisition of Genomic Health united two of the industry’s strongest brands, Cologuard and Oncotype DX®, and established the company’s position as a global leader in advanced cancer diagnostics. The company is working to improve screening, early detection, and treatment guidance throughout the cancer continuum.
William S. Dalton, Ph.D., M.D.
Founder, Senior Advisor, M2Gen
Dr. William “Bill” S. Dalton is the Founder of M2Gen, a national biotechnology subsidiary of Moffitt Cancer Center. He is the past President, CEO & Center Director of Moffitt Cancer Center, an NCI-Designated Comprehensive Cancer Center (2002-2012). Prior to his role as the President, CEO & Center Director of Moffitt Cancer Center, Dr. Dalton was the Dean of the University of Arizona College of Medicine.
Dr. Dalton is interested in the development of personalized cancer care and patient-centered outcomes research through Moffitt’s nationally renowned Total Cancer CareTM approach to developing evidence-based, personalized cancer treatments and information/decision tools for patients and clinicians. Total Cancer Care includes one of the largest cancer tumor bio-repositories and data warehouses in the U.S. dedicated to the development of personalized medicine. He is also recognized as a founder of ORIEN, an alliance of cancer centers who have agreed to use the Total Cancer Care protocol to generate and share data for collaborative research and learning. For his leadership in this area, Dr. Dalton was recognized as the 2010 recipient of the Personalized Medicine Coalition’s National Leadership in Personalized Medicine Award. Dr. Dalton’s basic and translational research interests focus on molecular mechanisms of drug resistance and drug discovery. He has over 200 publications, serves on several editorial boards, and has numerous patents in the fields of drug discovery and personalized medicine.
Stephen L. Eck, M.D., Ph.D.
Chief Medical Officer, MacroGenics
Stephen Eck, M.D., Ph.D., Senior Vice President, Clinical Development & Chief Medical Officer, joined MacroGenics in July 2020. Prior to MacroGenics, Dr. Eck served as chief medical officer of Immatics US, a company focused on TCR-based immunotherapies, and as president and chief executive officer of Aravive Biologics. Prior to these roles, Dr. Eck was Vice President and Global Head of Oncology Medical Sciences at Astellas Pharma, managing a portfolio of assets which included enzalutamide (Xtandi®), erlotinib (Tarceva®) and gilteritinib (Xospata®). Dr. Eck has also held leadership positions in drug development as Vice President of Translational Medicine and Pharmacogenomics at Eli Lilly and as Head of Clinical Oncology at Pfizer. He began his professional career at Monsanto in cancer target discovery and later joined the University of Pennsylvania, where he was the Anne B. Young Assistant Professor of Cancer Research and the Director of the Cancer Gene Therapy Program. Dr. Eck currently serves as a director for Luminex Corporation (NASDAQ: LMNX) and Circulogene, and on the boards of directors for the Personalized Medicine Coalition and the Central Pennsylvania Clinic. He is also a fellow of the American Association for the Advancement of Science. Dr. Eck holds a B.A. from Kalamazoo College, an M.S. and a Ph.D. from Harvard University, and an M.D. from the University of Mississippi School of Medicine with Residency and Fellowship training at the University of Michigan.
Lori Frank, Ph.D.
Senior Vice President, Research, Policy, and Programs, New York Academy of Medicine
Lori Frank, Ph.D., is Senior Vice President for Research, Policy, and Programs with the New York Academy of Medicine. Her work is focused on incorporating community perspectives in health research and policy to advance health equity. She is Past President of the International Society for Quality of Life Research, a professional society devoted to health outcomes assessment, and she serves on the Memory Screening Advisory Board of the Alzheimer's Foundation of America.
She completed her Health and Aging Policy Fellowship through the Congressional Fellowship Program and prior to that she founded and served as Program Director, Evaluation and Analysis, at the Patient-Centered Outcomes Research Institute (PCORI). She is an Affiliated Adjunct Scientist with the RAND Corporation and has held research and teaching positions with the Georgetown University Department of Psychiatry, the National Institute on Aging, and Medimmune LLC/AstraZeneca. She completed postdoctoral training in Mental Health Services Research with the VA Health Services Research and Development program. Her Ph.D. is in human development/gerontology from the Pennsylvania State University and her M.A. is in biopsychology from the Johns Hopkins University.
Vice President, Precision Medicine, Bristol Myers Squibb
Sarah is an accomplished leader and is responsible for leading a world-class research and development team of more than 100 scientists supporting translational sciences and diagnostics. She leads a team at Bristol Myers Squibb that supported more than 20 drug approvals, top-line results and other key regulatory milestones in a single year during the pandemic.
Prior to her time with Bristol Myers Squibb, Sarah was Head of Precision Medicine and Vice President at Celgene (which was acquired by Bristol Myers Squibb in 2019), where she built and led a world-class precision medicine team. Prior to Celgene, Sarah was the Global Head of Future Precision Medicine at Novartis, where she developed innovative solutions to support accurate and precise use of advanced diagnostic platforms. Sarah has also held multiple positions at Johnson & Johnson, Ortho Clinical Diagnostics, and Charles River Laboratories.
Kris Joshi, Ph.D.
Executive Vice President, President, Network Solutions, Change Healthcare
Mr. Joshi is Executive Vice President and President, Network Solutions for Change Healthcare. He initially joined Change Healthcare as Executive Vice President, Products in December 2013. Prior to that, Mr. Joshi was Global Vice President for health care product strategy for the Health Sciences Global Business Unit of the Oracle Corporation. He helped launch the health sciences business unit and successfully led two acquisitions for Oracle in the life sciences space. Before joining Oracle, Mr. Joshi served in senior strategy roles in IBM’s Global Sales and Distribution organization. Prior to that, Mr. Joshi was with McKinsey and Company, where he served Fortune 500 clients on strategy issues.
Mr. Joshi holds a Bachelor's degree in mathematics from Caltech, and a Ph.D. in physics from MIT.
President, American Association of Kidney Patients
Richard Knight received his MBA from the University of Virginia Darden School of Business and his B.A. from Hampton University. He is a results-oriented business strategist with diverse experience in public and private sectors in Finance, Accounting, Business Development, Healthcare, and Non-Profits. Entrepreneurial experience includes starting and running several ventures. Currently, he is a business strategist, providing patient engagement consulting for healthcare organizations and businesses developing tools designed to leverage patient input and preferences in their care plans and quality measures. He serves as an adjunct professor at Bowie State University (BSU). He is a founding member of BSU’s College of Business Advisory Council.
Mr. Knight is a healthcare professional and a former hemodialysis patient. He received a kidney transplant approximately fourteen years ago. He is President of the American Association of Kidney Patients (AAKP), which is the oldest and largest independent kidney patient organization in the United States.
Peter Maag, Ph.D.
CEO, Kyverna Therapeutics
Peter Maag, Ph.D., is the CEO of Kyverna Therapeutics. Dr. Maag is a seasoned global industry executive with a track record of transforming organizations and more than 20 years of executive management experience in the pharmaceutical and diagnostic industries.
Prior to joining Kyverna, Dr. Maag was Executive Chairman, President and CEO of CareDx, where he built the company from a small start-up into a public company and industry-leading powerhouse in transplantation through a series of BD&L and financing transactions. Prior to joining CareDx in 2012, Dr. Maag held multiple positions at Novartis with increasing responsibilities and worked at McKinsey & Company in New Jersey and Germany.
Dr. Maag received his Ph.D. from the University of Berlin, Germany, and studied pharmaceutical sciences in Heidelberg and London.
Anne-Marie Martin, Ph.D.
Senior Vice President & Global Head, Experimental Medicine, GlaxoSmithKline
Anne-Marie Martin is the SVP and Global Head of the Experimental Medicine Unit in Oncology R&D at GlaxoSmithKline. In this role, Annie leads the translational medicine effort to support asset development across the four Oncology R&D platforms in Immuno-Oncology (IO), Oncology Cell Therapy (OCT), Cancer Epigenetics (CE) and Synthetic Lethality (SL). This includes clinical biomarkers, companion diagnostics, supporting novel biomarker-driven clinical designs, the Oncology Clinical and Translational Consortium, and centralizing human subject sample handling and vendor buying power. In close collaboration with TA Clinical and the EDTs and MDTs, Annie plays a vital role in utilizing a personalized medicine approach to expedite the development of innovative therapeutics for treating various oncologic and hematologic indications.
Prior to joining GSK, Annie was the SVP, Global Head of Precision Medicine at Novartis Pharmaceuticals, where she was responsible for the development, implementation and execution of the Precision Medicine Strategy supporting all clinical development, registration and commercialization. While at Novartis, Annie shared in the successful delivery of 10 NDA/sNDAs across the pipeline and she led the development and successful approval of companion diagnostics in support of 6 clinical assets including midostaurin for Flt3 mutated AML, the first BRAF NGS assay for tafinlar and mekinist in NSCLC, ceritinib for ALK mutated NSCLC, capmatinib for MET mutated NSCLC, alpelisib for PIK3CA mutated breast cancer and BCR-ABL monitoring of major molecular response for Tasigna in CML.
Howard McLeod, Pharm.D.
Executive Clinical Director, Precision Health, Intermountain Healthcare
Dr. Howard McLeod is an internationally recognized expert in precision medicine, having made novel contributions at the discovery, translation, implementation, and policy levels. He is the Medical Director for Precision Medicine at the Geriatric Oncology Consortium. Dr. McLeod chaired the NHGRI eMERGE network external scientific panel for the past decade and was a recent member of both the FDA Committee on Clinical Pharmacology and the NIH Human Genome Advisory Council. Dr. McLeod has been recognized as a Fellow of both the American Society of Clinical Oncology and the American College of Clinical Pharmacy.
J. Brian Munroe
Vice President, Government Affairs, Bausch Health Companies Inc.
Brian Munroe is the founder and Past-President of the Personalized Medicine Coalition (PMC). He currently serves as the Chairman of PMC's Public Policy Committee and on the Executive Committee of PMC's Board of Directors.
A twenty-five year veteran of health care public policy, advocacy, and communications, Brian's areas of expertise include FDA legislation and regulations, Medicare and Medicaid reimbursement, federal and state tax policy, and the development of government policies to advance personalized medicine. As Chairman of the Public Policy Committee, he oversees PMC's public policy initiatives and its interactions with the federal government.
Brian has created successful, stand alone Government Affairs Departments from scratch at: SmithKline Beecham, Millennium Pharmaceuticals, and Endo Pharmaceuticals. He is currently Vice President, Government Affairs at Bausch Health Companies.
Elizabeth O'Day, Ph.D.
CEO and Founder, Olaris, Inc.
Dr. Elizabeth O'Day is the CEO and Founder of Olaris, Inc., a precision medicine company that uses a pioneering metabolomics platform and proprietary machine learning algorithms to fundamentally improve how disease is diagnosed and treated. Olaris identifies “biomarkers of response” (BoR) to stratify patients into optimal treatment groups, increasing survival rates, decreasing adverse events and reducing unnecessary healthcare costs. Dr. O'Day is also the co-chair of the World Economic Forum’s Global Future Council on Biotechnology, she serves on the advisory board for the Precision Medicine Initiative and was an invited speaker at the annual meeting in Davos. She was also a "nominated change maker" and invited to attend the first United State of Women Summit convened by the White House in 2016. She participated in Vice President Joe Biden's Cancer Moonshot Summit to discuss collaborative ways “to end cancer as we know it.”
Dr. O’Day is also the Founder of Lizzard Fashion, an apparel company that uses fashion to promote science, and Proyecto Chispa (Project Spark), a 501c3 non-profit that recycles electronics and uses the resale of parts to build computer centers in orphanages throughout the world.
Michael J. Pellini, M.D., M.B.A.
Managing Partner, Section 32
Dr. Pellini is Managing Partner of Section 32, a venture fund that invests in companies and inventors that are changing the way humans use technology and the way technology betters humanity. Previously, he served as CEO of Foundation Medicine (NASDAQ:FMI) from May 2011 until he transitioned to Chairman in February 2017.
He currently serves as a member of the Board of
Directors for Tango Therapeutics, Singular Genomics, Adaptive Biotechnologies
and the Mission Hospital Foundation. As a physician with more than twenty years of
executive experience with companies at the forefront of clinical diagnostics
and genomics, Dr. Pellini brings a breadth of understanding in personalized
medicine, with a particular interest and focus on defeating cancer. Dr. Pellini
is a member of the President’s Leadership Council at Thomas Jefferson
University and Jefferson Health, as well as the Advisory Board for Mission
Hospital’s Cancer Institute (Provident/St. Joseph Health).
Dr. Pellini received a B.A. from Boston College, an M.B.A. from Drexel University and an M.D. from Jefferson Medical College.
Board Member, 10x Genomics
Committed to changing the paradigm of cancer care, Kim Popovits led Genomic Health in revolutionizing the treatment of cancer through genomic-based diagnostic tests for breast, colon, and prostate cancers that address the over-treatment and optimal treatment of early-stage cancer, one of the greatest issues in health care today. She now serves as a board member with 10x Genomics.
Kim served as Genomic Health’s Chairman of the Board beginning in 2012, as its CEO and President beginning in 2009, and as its President and Chief Operating Officer beginning in 2002. Prior to joining Genomic Health, Kim served as Senior Vice President, Marketing and Sales, at the biotechnology company Genentech, Inc. During her 15 years at Genentech, Kim led the successful commercialization of 14 new therapies, including Herceptin®, the revolutionary targeted treatment that changed the way doctors treat a particularly aggressive form of breast cancer. Before joining Genentech, Kim served as division manager for American Critical Care, a division of American Hospital Supply Corporation.
Prasanth Reddy, M.D.
Senior Vice President, Global Enterprise Oncology Head, Labcorp
Dr. Reddy serves as Senior Vice President and Enterprise Oncology Head of Labcorp's enterprise oncology unit, which utilizes the combined assets of Labcorp's drug development and diagnostics businesses to help bring the right treatment to the right patient at the right time.
Dr. Reddy previously served as Vice President of Medical Affairs at Foundation Medicine, Inc. He is triple board-certified in internal medicine, medical oncology, and hematology. He previously practiced medicine and served in leadership positions for more than 10 years in various clinical settings including academia, private practice, and managed care.
Apostolia M. Tsimberidou, M.D., Ph.D.
Professor, Department of Investigational Therapeutics, The University of Texas MD Anderson Cancer Center
Since joining the faculty at The University of Texas MD Anderson Cancer Center in 2001, Dr. Tsimberidou's clinical research has focused on the development of therapeutic strategies for advanced hematologic malignancies and solid tumors. She has served as the Principal Investigator for 20 investigator-initiated clinical trials for the treatment of patients with advanced cancer. In 2007, she designed the Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT) trial in the Department of Investigational Cancer Therapeutics, and also developed the departmental protocol for the associated tissue bank. The hypothesis for IMPACT was to have tumor molecular profiling of patients with advanced cancer, then to treat patients with targeted therapies in order to counteract their molecular abnormalities. This in turn would improve the clinical outcomes of patients with advanced cancer. Results demonstrated that tumor molecular profiling and identification of tumor specific molecular aberrations and selected therapy based on these abnormalities is associated with higher rates of response, time to treatment failure, and survival in patients with advanced cancer compared to the standard approach.
Michael J. Vasconcelles, M.D.
Senior Advisor, Frazier Life Sciences
Michael Vasconcelles, M.D., is currently a Senior Advisor at Frazier Life Sciences, a firm that invests in and builds companies developing and commercializing novel therapeutics. Previously, Dr. Vasconcelles was Chief Medical Officer of Flatiron Health, a health technology company working to improve patient care and accelerate cancer research through its products and services. Flatiron’s health technology platform, products, and research datasets help oncologists and life sciences researchers improve the lives of cancer patients through enhanced care delivery, clinical research, and the use of real-world data to accelerate oncology research and decision-making.
Prior to joining Flatiron, Dr. Vasconcelles held senior management positions at Unum Therapeutics (now Cogent Biosciences), Takeda/Millennium, Genzyme Corporation, and Sanofi Oncology. He has also served as a faculty member of Harvard Medical School and as an Associate Physician at Brigham and Women's Hospital and the Dana Farber Cancer Institute.
Jay G. Wohlgemuth, M.D.
Chief Medical Officer, Senior Vice President, Quest Diagnostics
Jay G. Wohlgemuth, M.D., is Chief Medical Officer and Senior Vice President, Research & Development and Medical for Quest Diagnostics. Based at Quest Diagnostics Nichols Institute, in San Juan Capistrano, California, Dr. Wohlgemuth is responsible for Research & Development (R&D), Medical Affairs and Medical/Lab Quality. In addition, he is responsible for improving outcomes for employees who use Quest's health benefits.
Dr. Wohlgemuth has many years of experience in medical diagnostics and research and development. He rejoined Quest in 2016 from HealthTap, a health information start-up, where he served as Senior Vice President and Chief Healthcare Officer. Prior to that, he was Senior Vice President, R&D, Medical and Chief Scientific Officer with Quest. Dr. Wohlgemuth originally joined Quest in 2009 from Genentech, where he was Director, Clinical Diagnostics, ITGR (Immunology, Tissue Growth and Repair) and Global Development Team Leader for Ocrulizumab. He also served as Vice President, Research and Development for VIA Pharmaceuticals and as Chief Medical Officer for the molecular diagnostics company XDx, a company he co-founded. In addition, Dr. Wohlgemuth served as Vice President, Research & Development for XDx. For his work at XDx he was awarded Technology Pioneer 2005 at the World Economic Forum in Davos. He serves on the Board of Directors for the Diagnostic Labs of Oklahoma and The Anne and Henry Zarrow Charitable Foundation.